News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Isis Pharmaceuticals, Inc. (ISIS) Spinoff Altair Therapeutics Shut Down After Mid-Stage Asthma Study Fails



2/4/2011 7:51:35 AM

Xconomy -- San Diego-based Altair Therapeutics, a spinoff from Isis Pharmaceuticals (NASDAQ: ISIS), has shut down operations after the startup’s only drug candidate failed in a mid-stage clinical trial against asthma, Xconomy has learned.

Read at Xconomy


comments powered by Disqus
Xconomy
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES